ReviewWorld journal of gastrointestinal pathophysiology2015
Current therapy of pediatric Crohn's disease.
Review in World journal of gastrointestinal pathophysiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Tumor necrosis factor-alpha antagonists for treatment of pediatric Crohn's disease.The Cochrane database of systematic reviews · 2025Pooled it
- Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers.World journal of gastroenterology · 2025Review
- New-Onset Perianal Eroded Lesion in a Pediatric Patient.Pediatric dermatology · 2025Article
- Review
- Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction.Frontiers in cellular and infection microbiology · 2025Review
- Establishment and Characterization of Patient-Derived Intestinal Organoids from Pediatric Crohn's Disease Patients.Pediatric gastroenterology, hepatology & nutrition · 2024Article
- Endoscopic Guided Dilations without Intralesional Corticosteroid Injections: Pediatric Crohn's Patients Case Series.Reports (MDPI) · 2024Article
- Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases.Nutrients · 2023Review
- Article
- Case Series of Precision Delivery of Methylprednisolone in Pediatric Inflammatory Bowel Disease: Feasibility, Clinical Outcomes, and Identification of a Vasculitic Transcriptional Program.Journal of clinical medicine · 2023Article
- Growth hormone alters gross anatomy and morphology of the small and large intestines in age- and sex-dependent manners.Pituitary · 2022Article
- The Identification of a Novel Thiopurine S-Methyltransferase Allele,Pharmacogenomics and personalized medicine · 2020Article
- Natural history of children with mild Crohn's disease.World journal of gastroenterology · 2019Article
- Young mice expel the tapeworm Hymenolepis diminuta and are protected from colitis by triggering a memory response with worm antigen.American journal of physiology. Gastrointestinal and liver physiology · 2018Article
- Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol.BMJ open · 2018Article
- Diagnosis and management of inflammatory bowel disease in children.BMJ (Clinical research ed.) · 2017Review
- The effect of NOD2 on the microbiota in Crohn's disease.Current opinion in biotechnology · 2016Review
- Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease: infliximab may normalize activation patterns.Oncotarget · 2016Article
- Environmental Enteric Dysfunction in Children.Journal of pediatric gastroenterology and nutrition · 2016Review
- Convergence of External Crohn's Disease Risk Factors on Intestinal Bacteria.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis, are chronic relapsing and remitting diseases of the bowel, with an unknown etiology and appear to involve interaction between genetic susceptibility, environmental factors and the immune system. Although our knowledge and understanding of the pathogenesis and causes of IBD have improved significantly, the incidence in the pediatric population is still rising. In the last decade more drugs and treatment option have become available including 5-aminosalicylate, antibiotics, corticosteroids, immunomodulators and biological agents. Before the use of anti-tumor necrosis factor (TNF)-α became available to patients with IBD, the risk for surgery within five years of diagnosis was very high, however, with anti-TNF-α treatment the risk of surgery has decreased significantly. In the pediatric population a remission in disease can be achieved by exclusive enteral nutrition. Exclusive enteral nutrition also has an important role in the improvement of nutritional status and maintained growth. In this review we summarize the current therapeutic treatments in CD. The progress in the treatment options and the development of new drugs has led to optimized tactics for achieving the primary clinical goals of therapy - induction and maintenance of remission while improving the patient's growth and overall well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.